0.7400USD+9.48%Mkt Cap: 5.66M USDP/E: —Last update: 2026-06-01
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.66M USD
Enterprise Value-11.18M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.92M USD
Revenue/Share—
Last Price0.7400 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA3.46
EV/Revenue—
P/S—
P/B0.59
EPS (TTM)-0.48
EPS (Forward)-0.35
52W Range
0.53103% of range7.000
52W High7.000 USD
52W Low0.5310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.16%
ROA-10.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.26M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-85.97%
Net Debt-16.26M USD
Net Debt/EBITDA5.04
Balance Sheet
Debt/Equity0.00
Current Ratio2.12
Quick Ratio2.10
Book Value/Sh1.135 USD
Cash/Share2.146 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateJan 16, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.73M
Float5.35M
Insiders4.30%
Institutions9.47%
Short Interest
Short Ratio1.3d
Short % Float0.80%
Short % Out.0.71%
Shares Short53.59K
Short (prev mo.)101.08K
Technical
SMA 500.7244 (+2.2%)
SMA 2001.129 (-34.5%)
Beta2.11
S&P 52W Chg27.94%
Avg Vol (30d)45.49K
Avg Vol (10d)44.67K
Technical Indicators
RSI (14)49.5
MACD-0.0301
MACD Signal-0.0359
MACD Hist.+0.0058
BB Upper0.7778 USD
BB Middle0.6657 USD
BB Lower0.5536 USD
BB Width33.68%
ATR (14)0.0405 USD
Vol Ratio (20d)0.91x